Natural history of Acinetobacter baumannii infection in mice-Reference-Cited by-同舟云学术

Natural history of Acinetobacter baumannii infection in mice

Published:2019-07-18 Issue:7 Volume:14 Page:e0219824
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Luna Brian M.^ORCID,Yan Jun^ORCID,Reyna Zeferino^ORCID,Moon Eugene,Nielsen Travis B.^ORCID,Reza Hernan^ORCID,Lu Peggy^ORCID,Bonomo Robert,Louie Arnold,Drusano George^ORCID,Bulitta Jürgen^ORCID,She Rosemary^ORCID,Spellberg Brad

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference18 articles.

1. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis;E Tacconelli;Lancet Infect Dis,2018

2. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges;D Wong;Clin Microbiol Rev,2017

3. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America;HW Boucher;Clin Infect Dis,2009

4. Establishment of Experimental Murine Peritonitis Model with Hog Gastric Mucin for Carbapenem-Resistant Gram-Negative Bacteria;JY Park;Infect Chemother,2017

5. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii;S-R Chiang;Crit Care Med,2009

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival and virulence of Acinetobacter baumannii in microbial mixtures;BMC Microbiology;2024-09-06

2. Polymyxins retain in vitro activity and in vivo efficacy against “resistant” Acinetobacter baumannii strains when tested in physiological conditions;Antimicrobial Agents and Chemotherapy;2024-09-06

3. Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models;Antimicrobial Agents and Chemotherapy;2024-03-06

4. Clinical assays rapidly predict bacterial susceptibility to monoclonal antibody therapy;JCI Insight;2024-01-23

5. Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s Perspective;Antibiotics;2024-01-11